MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bcp.15690

Медицинская библиотека · British journal of clinical pharmacology · 2023

Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more.

Boone Niels W, Moes Dirk Jan A R, Ramiro Sofia, Mostard Remy L M, Magro-Checa Cesar, van Dongen Christel M P, Gronenschild Michiel, van Haren Eric, Buijs Jacqueline, de Vries Annick, Peeters Ralph, Landewé Robert B M, Wong Dennis R

СтатьяПеревод пока не подготовлен

Аннотация

AIMS: We aim to evaluate the clinical pharmacokinetics of a single dose interleukin-6 (IL-6) antibody tocilizumab (TCZ) in methylprednisolone (MP)-treated COVID-19 patients with cytokine storm syndrome (CSS).

METHODS

MP pre-treated patients with COVID-19-associated CSS, defined as at least two elevations of C-reactive protein (CRP) >100 mg/L, ferritin >900 μg/L or D-dimers >1500 μg/L, received intravenous TCZ (8 mg/kg, max. 800 mg) upon clinical deterioration. A nonlinear-mixed effects model was developed based on TCZ serum concentrations and dosing information. Population pharmacokinetic parameters were estimated and concentration-time profiles were plotted against individual predicted values. Fixed dose simulations were subsequently performed based on the final model.

RESULTS

In total 40 patients (mean [SD] age: 62 [12] years, 20% female, body weight: 87 [17] kg) with COVID-19 induced CSS were evaluated on pharmacokinetics and laboratory parameters. A biphasic elimination of TCZ serum concentration was described by a homogeneous population pharmacokinetic model. Serum TCZ concentrations above the 1 μg/L target saturation threshold were covered for 16 days in all evaluated patients treated with a single dose of 8 mg/kg. In a simulation with TCZ 400 mg fixed dose, this condition of full IL-6 receptor occupancy at minimum serum concentration was also met.

CONCLUSIONS

A single dose (8 mg/kg, max. 800 mg) is sufficient to cover a period of 16 days of IL-6-mediated hyperinflammation in COVID-19-induced CSS in MP-treated patients. Based on body weight PK simulations, a fixed-dose tocilizumab of 400 mg should be considered to prevent overtreatment, future drug shortage and unnecessary drug expenditure.

Для цитирования: Boone Niels W, Moes Dirk Jan A R, Ramiro Sofia, Mostard Remy L M, Magro-Checa Cesar, van Dongen Christel M P, Gronenschild Michiel, van Haren Eric, Buijs Jacqueline, de Vries Annick, Peeters Ralph, Landewé Robert B M, Wong Dennis R. Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more.. British journal of clinical pharmacology. 2023. DOI: 10.1111/bcp.15690.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.